Breaking the stromal barrier in pancreatic cancer: Advances and challenges
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2024-01 · 1879 (1) · 189065
DOI: 10.1016/j.bbcan.2023.189065 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2024-01. Verfasst von Mohana Chakkera und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, Heersink School of Medicine, University of Alabama, Birmingham, AL 35233, USA. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Cancer-Associated Fibroblasts. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 185 Literaturangaben.
Abstract (Originalsprache)
Pancreatic cancer (PC) remains a leading cause of mortality worldwide due to the absence of early detection methods and the low success rates of traditional therapeutic strategies. Drug resistance in PC is driven by its desmoplastic stroma, which creates a barrier that shields cancer niches and prevents the penetration of drugs. The PC stroma comprises heterogeneous cellular populations and non-cellular components involved in aberrant ECM deposition, immunosuppression, and drug resistance. These components can influence PC development through intricate and complex crosstalk with the PC cells. Understanding how stromal components and cells interact with and influence the invasiveness and refractoriness of PC cells is thus a prerequisite for developing successful stroma-modulating strategies capable of remodeling the PC stroma to alleviate drug resistance and enhance therapeutic outcomes. In this review, we explore how non-cellular and cellular stromal components, including cancer-associated fibroblasts and tumor-associated macrophages, contribute to the immunosuppressive and tumor-promoting effects of the stroma. We also examine the signaling pathways underlying their activation, tumorigenic effects, and interactions with PC cells. Finally, we discuss recent pre-clinical and clinical work aimed at developing and testing novel stroma-modulating agents to alleviate drug resistance and improve therapeutic outcomes in PC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology and Oncology, Heersink School of Medicine, University of Alabama, Birmingham, AL 35233, USA.
- Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
- Department of Oncology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
- Department of Hematology and Oncology, Heersink School of Medicine, University of Alabama, Birmingham, AL 35233, USA. Electronic address: purnachandraganji@uabmc.edu.
Zitieren
APA
Chakkera, M., Foote, J. B., Farran, B., & Nagaraju, G. P. (2024). Breaking the stromal barrier in pancreatic cancer: Advances and challenges. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1879(1), 189065. https://doi.org/10.1016/j.bbcan.2023.189065
Vancouver
Chakkera M, Foote JB, Farran B, Nagaraju GP. Breaking the stromal barrier in pancreatic cancer: Advances and challenges. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2024;1879(1):189065. doi:10.1016/j.bbcan.2023.189065
BibTeX
@article{Chakkera2024,
author = {Chakkera, Mohana and Foote, Jeremy B and Farran, Batoul and Nagaraju, Ganji Purnachandra},
title = {Breaking the stromal barrier in pancreatic cancer: Advances and challenges},
journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
year = {2024},
volume = {1879},
number = {1},
pages = {189065},
doi = {10.1016/j.bbcan.2023.189065}
}
EUVIMED